Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1678
This examiner grants 44% of resolved cases
Constantina E. Stavrou is an examiner in Art Unit 1632 of Tech Center 1600, with 87 resolved cases. Her allowance rate is 43.7%, and the median days to allowance is 1434. These figures suggest a thorough examination process that often takes several years to reach a conclusion. The 87 resolved cases provide a baseline for expectations regarding the timeline and success probability in Tech Center 1600.
The interview lift of 36.9% indicates that direct communication is a valuable strategy for applicants. By engaging in an interview, practitioners may significantly improve their chances of success beyond the 43.7% baseline, making it a recommended tactic for this examiner. The 36.9% lift shows that verbal dialogue is effective in resolving the complex issues often found in Art Unit 1632. Applicants should factor the 1434 median days to allowance into their long-term planning, using interviews as a tool to advance prosecution and potentially reach a grant more efficiently.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18042040 | PROCESS SYSTEM FOR BIOREACTOR-BASED CLEAN MEAT PRODUCTION | Final Rejection | Merck Patent GmbH |
| 16707681 | PRE-SHAPED ALLOGRAFT IMPLANT FOR RECONSTRUCTIVE SURGICAL USE AND METHODS OF MANUFACTURE AND USE | Non-Final OA | Allosource |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | Final Rejection | ImmunityBio, Inc. |
| 17545416 | METHODS FOR CONTROLLED INDUCTION OF BIOENGINEERED NEUROEPITHELIAL TISSUES AND 3-D NEUROEPITHELIAL TUBES | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17928355 | CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS AND METHODS OF USE THEREOF | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18490714 | METHOD FOR ISOLATING HUMAN DERMAL FIBROBLASTS | Final Rejection | KING'S COLLEGE LONDON |
| 18690594 | SALMONELLA ENGINEERED FOR NONTOXIC COLONIZATION OF TUMORS | Non-Final OA | Regents of the University of Minnesota |
| 18288345 | VIRAL VECTOR PRODUCTION SYSTEM | Non-Final OA | Novartis AG |
| 17282117 | MODULAR BIOFABRICATION PLATFORM FOR DIVERSE TISSUE ENGINEERING APPLICATIONS AND RELATED METHOD THEREOF | Non-Final OA | University of Virginia Patent Foundation |
| 17474178 | VITRO ASSAY FOR DRUG DISCOVERY OF VALVULAR HEART DISEASE | Final Rejection | UNIVERSITY OF SOUTH CAROLINA |
| 18023289 | COMPOSITIONS AND METHODS FOR GENERATING HUMAN YOLK SAC-LIKE HEMATOPOIETIC CELLS | Final Rejection | UNIVERSITY HEALTH NETWORK |
| 17057130 | METHODS AND COMPOSITIONS COMPRISING TANKYRASE INHIBITORS FOR GENERATING INSULIN PRODUCING CELLS | Final Rejection | UNIVERSITY HEALTH NETWORK |
| 18572723 | ADENO-ASSOCIATED VIRAL (AAV) VECTORS FOR TISSUE-TARGETED EXPRESSION OF THERAPEUTIC GENES | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 17867335 | COMPOSITIONS AND METHODS FOR GENERATION OF RETINAL GANGLION CELLS FROM INDUCIBLE PLURIPOTENT STEM CELLS FOR THE TREATMENT OF PROGRESSIVE OPTIC NEUROPATHIES, INCLUDING GLAUCOMA | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18546761 | Methods of Expanding Cholangiocytes | Non-Final OA | Cambridge Enterprise Limited |
| 18575265 | DNA ORIGAMI STRUCTURE AND PROTEIN NANOPORE CONSTRUCT | Non-Final OA | Illumina, Inc. |
| 17931440 | COMPOSITIONS OF INDUCED PLURIPOTENT STEM CELL-DERIVED CELLS AND METHODS OF USE THEREOF | Final Rejection | FUJIFILM Cellular Dynamics, Inc. |
| 18248443 | Method for Inducing Differentiated Cells Into Pluripotent Endoderm Stem Cells and Application Thereof | Final Rejection | CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES |
| 17799870 | Method for providing personalized cells with chimeric antigen receptors (CAR) against tumor microenvironment cells | Non-Final OA | Miltenyi Biotec B.V. & Co. KG |
| 18562448 | SECRETED SPLICING VARIANT OF KLOTHO FOR TREATING BONE DISORDERS | Non-Final OA | INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy